Compositions and methods for treating pulmonary hypertension
In some aspects, the disclosure relates to GDF/BMP antagonists and methods of using GDF/BMP antagonists to treat, prevent, or reduce the progression rate and/or severity of pulmonary hypertension (PH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PH-associated complications. The disclosure also provides methods of using a GDF/BMP antagonist to treat, prevent, or reduce the progression rate and/or severity of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. The disclosure further provides methods of using a GDF/BMP antagonist to reduce right ventricular systolic pressure in a subject in need thereof.
1. A method of treating pulmonary arterial hypertension, comprising administering to a patient in need thereof an effective amount of a polypeptide comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 40, wherein the polypeptide binds to one or more ligands selected from the group consisting of: activin A, activin B, GDF11, BMP10, GDF8, and BMP6.
2. The method of claim 1 , wherein the polypeptide comprises an amino acid sequence that is at least 99% identical to the amino acid sequence of SEQ ID NO: 40.
3. The method of claim 1 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 40.
4. The method of claim 1 , wherein the polypeptide consists of the amino acid sequence of SEQ ID NO: 40.
5. The method of claim 1 , wherein the polypeptide comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 42.
6. The method of claim 1 , wherein the polypeptide comprises an amino acid sequence that is at least 99% identical to the amino acid sequence of SEQ ID NO: 42.
7. The method of claim 1 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 42.
8. The method of claim 1 , wherein the polypeptide consists of the amino acid sequence of SEQ ID NO: 42.
9. The method of claim 1 , wherein the patient has resting pulmonary arterial pressure (PAP) of at least 25 mm Hg.
10. The method of claim 1 , wherein the method reduces PAP in the patient.
11. The method of claim 1 , wherein the patient has Functional Class II or Class III pulmonary hypertension as recognized by the World Health Organization.
12. The method of claim 11 , wherein the method prevents or delays pulmonary hypertension Functional Class progression.
13. The method of claim 1 , wherein the polypeptide is part of a homodimer protein complex.
14. The method of claim 1 , wherein the polypeptide is glycosylated.
15. The method of claim 1 , comprising further administering to the patient an additional active agent and/or supportive therapy for treating pulmonary hypertension.
16. The method of claim 15 , wherein the additional active agent and/or supportive therapy for treating pulmonary hypertension is selected from the group consisting of: prostacyclin and derivatives thereof; prostacyclin receptor agonists; endothelin receptor; calcium channel blockers; anticoagulants; diuretics; oxygen therapy; atrial septostomy; pulmonary thromboendarterectomy; phosphodiesterase type 5 inhibitors; activators of soluble guanylate cyclase; ASK-1 inhibitors; NF-κB antagonists; lung and/or heart transplantation.
17. The method of claim 1 , wherein the patient has been treated with one or more vasodilators.
18. The method of claim 1 , wherein the patient has been treated with one or more agents selected from the group consisting of: phosphodiesterase type 5 inhibitors, soluble guanylate cyclase stimulators, prostacyclin receptor agonist, and endothelin receptor antagonists.
19. The method of claim 18 , wherein the one or more agents is selected from the group consisting of: bosentan, sildenafil, beraprost, macitentan, selexipag, epoprostenol, treprostinil, iloprost, ambrisentan, and tadalafil.
20. The method of claim 1 , wherein the method further comprises administration of one or more vasodilators.
21. The method of claim 1 , wherein the method further comprises administration of one or more agents selected from the group consisting of: phosphodiesterase type 5 inhibitors, soluble guanylate cyclase stimulators, prostacyclin receptor agonist, and endothelin receptor antagonists.
22. The method of claim 21 , wherein the one or more agents is selected from the group consisting of: bosentan, sildenafil, beraprost, macitentan, selexipag, epoprostenol, treprostinil, iloprost, ambrisentan, and tadalafil.